Dr. Sonpavde on real-world treatment patterns and outcomes with frontline therapy in advanced urothelial carcinoma

Guru P. Sonpavde, MD, director of the Bladder Cancer Program at Dana-Farber Cancer Institute, and associate professor of Medicine at Harvard Medical School, discusses the 2022 ASCO Annual Meeting abstract, “Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.”